Real-world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non-valvular atrial fibrillation patients in England.
atrial fibrillation
bleeding
health economics
ischaemic stroke
real-world data
Journal
Journal of evaluation in clinical practice
ISSN: 1365-2753
Titre abrégé: J Eval Clin Pract
Pays: England
ID NLM: 9609066
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
08
10
2019
revised:
18
03
2020
accepted:
22
03
2020
pubmed:
22
4
2020
medline:
29
7
2021
entrez:
22
4
2020
Statut:
ppublish
Résumé
Several novel oral anticoagulants (NOACs) are licensed for atrial fibrillation (AF) treatment in the United Kingdom. We describe the incidence and mortality from ischaemic stroke and major bleeding in non-valvular atrial fibrillation (NVAF) patients in England, including treatment patterns before/following introduction of NOACs, healthcare resource utilization (HRU), and costs post-onset of these events. Data were extracted from the UK Clinical Practice Research Datalink linked to Hospital Episode Statistics secondary care and Office for National Statistics mortality data. Of 42 966 patients with a first AF record between 2011 and 2016, 9143 patients (21.3%) remained without AF (antiplatelets/antithrombotics) treatment post-index diagnosis. The proportion of patients receiving aspirin for ≥3 months post-index declined during the study (50.6%-5.5%), irrespective of CHA These data provide temporal insights into AF treatment patterns and outcomes for NVAF patients in England and highlight the need to review higher stroke risk AF patients not receiving antiplatelet/antithrombotic prescriptions.
Identifiants
pubmed: 32314853
doi: 10.1111/jep.13400
pmc: PMC7891325
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-133Subventions
Organisme : Roche Diagnostics International Ltd, Switzerland
Organisme : Roche Real-World Data Group, Diagnostics Information Solutions, USA
Informations de copyright
© 2020 The Authors. Journal of Evaluation in Clinical Practice published by John Wiley & Sons Ltd.
Références
Biostatistics. 2000 Mar;1(1):35-47
pubmed: 12933524
Cardiol Res Pract. 2012;2012:645469
pubmed: 23082276
Circulation. 2012 Aug 14;126(7):860-5
pubmed: 22891166
Am J Cardiol. 2017 Nov 15;120(10):1820-1829
pubmed: 28867127
Eur Heart J. 2018 Aug 21;39(32):2975-2983
pubmed: 29982405
Am J Med. 2015 Dec;128(12):1306-13.e1
pubmed: 26239094
BMJ. 2017 Nov 28;359:j5058
pubmed: 29183961
Heart. 2017 Feb 15;103(4):307-314
pubmed: 27647168
J Am Coll Cardiol. 2017 May 23;69(20):2475-2484
pubmed: 28521884
J Neurol Neurosurg Psychiatry. 2005 May;76(5):679-83
pubmed: 15834026
Thromb Haemost. 2016 Oct 28;116(5):975-986
pubmed: 27538358
Cardiol Clin. 2019 May;37(2):119-129
pubmed: 30926013
Europace. 2017 Jun 1;19(6):937-947
pubmed: 27209573
Am J Med. 2010 Jul;123(7):638-645.e4
pubmed: 20609686
J Eval Clin Pract. 2021 Feb;27(1):119-133
pubmed: 32314853
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
BMJ Open. 2015 Oct 21;5(10):e008456
pubmed: 26490097
Appl Health Econ Health Policy. 2012 Jul 1;10(4):249-59
pubmed: 22540235
Circulation. 2014 Dec 2;130(23):2071-104
pubmed: 24682348
BMJ Open. 2014 Jan 27;4(1):e003839
pubmed: 24468720
Heart. 2004 Mar;90(3):286-92
pubmed: 14966048
Eur Heart J. 2016 Oct 07;37(38):2882-2889
pubmed: 27357359
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
BMJ Open. 2017 Sep 25;7(9):e015363
pubmed: 28951401
BMJ Open. 2018 Jan 24;8(1):e019638
pubmed: 29371284